PP405 shows promise for hairfollicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Breezula offers modest hairgrowth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
KX-826 initially improves hairgrowth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
Microneedling is effective for hairgrowth, especially when combined with finasteride and minoxidil, but concerns exist about potential long-term skin damage. Users report increased collagen and elastin deposition, but the long-term effects on the scalp remain uncertain.
Whether topical caffeine can be as effective for hairgrowth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.
Androgenetic alopecia is caused by DHT affecting hairgrowth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hairgrowth.
The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.
PP405 is a potential hair loss treatment that may activate dormant hairfollicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
PP405 is a promising new hair loss treatment that may reactivate dormant hairfollicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
UCLA's PP405 shows promise in reactivating dormant hairfollicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hairfollicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hairgrowth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.
Topical minoxidil and oral finasteride can effectively improve hairgrowth and slow hair loss, though results may vary. Consistency is important for achieving significant improvement.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hairfollicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
SCUBE3, a protein linked to hairgrowth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hairgrowth therapy.
Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hairfollicles is considered a potential solution, but it's currently not feasible.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
The effects of finasteride and dutasteride on beard growth, whether minoxidil would help with facial hair loss caused by DHT blockers, and anecdotal evidence from users who have experienced either decreased or increased facial hair density while using these treatments.
Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hairgrowth.
A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.
A user humorously suggested smoking minoxidil in a blunt as an alternative hairgrowth method, sparking a satirical discussion on unconventional and unsafe ways to use minoxidil. The conversation included various suggestions like oral pills, rectal administration, and other absurd methods, with some users warning against the dangers of such practices.
A user shared their experience with hair loss treatments, noting improvement after switching from minoxidil and finasteride to dutasteride. They observed new hairgrowth and reduced scalp inflammation, expressing hope for further progress.
Hair loss treatments, specifically the use of finasteride, microneedling and potentially oral minoxidil. People discussed their experiences with finasteride, its effects on sexual behaviors, as well as potential solutions such as tadalafil or using other growth factor signal peptides for hope in curing male pattern baldness.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hairfollicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
A user shared their experience with hair loss treatments, switching from 1mg finasteride and topical minoxidil to 5mg oral minoxidil and oral dutasteride, noting improvements despite shedding phases. Other users discussed the hairgrowth cycle, treatment effects, and shared advice on managing hair loss, including buzzing hair and maintaining mental health.
Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hairgrowth.
A user reported losing hair after 7 months of using oral minoxidil, finasteride, and dutasteride, but others reassured that this is likely just a shedding phase where old hairs fall out to make way for new growth. Some users experience sheds every 7-8 months and suggest staying consistent with treatment.
A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hairgrowth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.